The Cure Scientific Working Group (SWG) represents a new and exciting focus area for the DC CFAR that builds upon the expertise and interest of affiliated investigators, and was catalyzed by the recruitment of Dr. Douglas Nixon and his investigative team to Washington, DC. The Cure SWG was created at the start of Year 5 of the DC D-CFAR to bring together basic research scientists in DC to focus on the ?cure agenda?. The Cure SWG has already identified a core group of DC D-CFAR basic science investigators whose research is related to the HIV cure agenda, and developed two regular scientific meetings that will serve as a forum for discussion and collaboration among SWG members. Two new and highly innovative HIV cure research programs are being developed: ?To cure a child of AIDS?, and ?Identification of cure ready patients?. Plans are being made to establish collaborations on HIV cure research with other CFARs. The Cure SWG has worked with the DC D-CFAR Developmental Core to ensure that dedicated pilot award RFAs and microgrants will be targeted towards the HIV cure agenda.
The Specific Aims of the Cure SWG are: 1) To provide a collaborative, cross-institutional platform that supports the discovery, development, and implementation of innovative basic HIV/AIDS cure research; 2) To support the development of manuscripts and other dissemination activities based on this research to ensure maximum potential for impacting HIV/AIDS cure science; and 3) To support early stage investigators in HIV/AIDS cure research, with an emphasis on women and minority researchers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI117970-05
Application #
9707734
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
George Washington University
Department
Type
DUNS #
043990498
City
Washington
State
DC
Country
United States
Zip Code
20052
Macedo, Amanda B; Resop, Rachel S; Martins, Laura J et al. (2018) Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses 34:769-777
Calabrese, Sarah K; Earnshaw, Valerie A; Magnus, Manya et al. (2018) Sexual Stereotypes Ascribed to Black Men Who Have Sex with Men: An Intersectional Analysis. Arch Sex Behav 47:143-156
Desrosiers, Aimee; Levy, Matthew; Dright, Aurnell et al. (2018) A Randomized Controlled Pilot Study of a Culturally-Tailored Counseling Intervention to Increase Uptake of HIV Pre-exposure Prophylaxis Among Young Black Men Who Have Sex with Men in Washington, DC. AIDS Behav :
Ghosh, Mimi; Daniels, Jason; Pyra, Maria et al. (2018) Impact of chronic sexual abuse and depression on inflammation and wound healing in the female reproductive tract of HIV-uninfected and HIV-infected women. PLoS One 13:e0198412
Houzet, Laurent; PĂ©rez-Losada, Marcos; Matusali, Giulia et al. (2018) Seminal Simian Immunodeficiency Virus in Chronically Infected Cynomolgus Macaques Is Dominated by Virus Originating from Multiple Genital Organs. J Virol 92:
Macedo, Amanda B; Novis, Camille L; De Assis, Caroline M et al. (2018) Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight 3:
Ren, Yanqin; Korom, Maria; Truong, Ronald et al. (2018) Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. J Virol 92:
Orekhov, Alexander N; Pushkarsky, Tatiana; Oishi, Yumiko et al. (2018) HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages. Exp Mol Pathol 105:202-207
Huang, Szu-Han; Ren, Yanqin; Thomas, Allison S et al. (2018) Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J Clin Invest 128:876-889
Adzhubei, Alexei A; Anashkina, Anastasia A; Tkachev, Yaroslav V et al. (2018) Modelling interaction between HIV-1 Nef and calnexin. AIDS 32:2103-2111

Showing the most recent 10 out of 98 publications